The race to build the next generation of weight-loss drugs

Overview

Kailera Therapeutics just pulled off the largest biotech initial public offering in history, raising $625 million and watching its shares surge 62.5% on the first day of trading. The company, founded less than two years ago with drugs licensed from a Chinese pharmaceutical firm, is now valued at roughly $3.5 billion — without a single approved product. That a startup built entirely around next-generation obesity drugs can command this kind of investor enthusiasm tells you where the pharmaceutical industry's center of gravity has shifted.

The GLP-1 receptor agonist market — drugs that mimic gut hormones to suppress appetite — has ballooned from a niche diabetes treatment into what analysts project will be an $80 billion market by decade's end. Novo Nordisk and Eli Lilly currently dominate with Wegovy and Zepbound, but the field is fragmenting fast. At least a dozen companies are racing to develop pills, longer-acting injections, and multi-target molecules that could leapfrog the incumbents.

Kailera's record-breaking debut is the latest signal that Wall Street sees this market as far from settled.

Why it matters

Obesity drugs that actually work are changing healthcare economics — and the scramble to build better ones is attracting more capital than any biotech sector in history.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

$625M

Kailera IPO raise

Largest biotech initial public offering in history, surpassing Moderna's $600 million in 2018

62.5%

First-day share price gain

Kailera shares opened at $26 against a $16 IPO price on April 18, 2026

12.1%

Ribupatide weight loss at 26 weeks

Oral formulation in Phase 2 trial; injectable version now in global Phase 3 studies

$80B

Projected GLP-1 obesity market by 2030

Up from roughly $14 billion in 2024, driven by expanding indications and new entrants

12+

Companies with obesity drugs in clinical trials

Including Novo Nordisk, Eli Lilly, Amgen, Viking Therapeutics, Structure Therapeutics, and Kailera

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play

Timeline Five events from this story — drag them oldest to newest. Log in to play

Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Ron Renaud

Leading Kailera through its public debut and Phase 3 clinical program

John F. Milligan

Serving as board chair

Organizations Involved

Kailera Therapeutics

Clinical-stage biopharmaceutical company

Newly public; advancing four obesity drug candidates through clinical trials

A Bain Capital-backed obesity drug developer that licensed four metabolic disease assets from China's Hengrui Pharmaceuticals and is advancing them through global clinical trials.

Jiangsu Hengrui Pharmaceuticals

Pharmaceutical company

Kailera's licensor; advancing ribupatide in China independently

One of China's largest pharmaceutical companies, Hengrui developed ribupatide and licensed global rights outside greater China to Kailera while continuing its own clinical program domestically.

Novo Nordisk

Pharmaceutical company

GLP-1 market leader facing growing competition and declining sales forecasts

The Danish drugmaker that created the GLP-1 obesity drug category with Wegovy (semaglutide) now faces a projected 5-13% sales decline in 2026 as competitors multiply and pricing pressure intensifies.

Eli Lilly and Company

Pharmaceutical company

Surpassing Novo Nordisk in GLP-1 market share with expanding product line

Lilly's tirzepatide (marketed as Mounjaro and Zepbound) has taken a clear lead in GLP-1 market share, with the company forecasting $80-83 billion in 2026 sales.

Bain Capital Life Sciences

Private equity / venture capital

Lead investor in Kailera Therapeutics

Bain Capital Life Sciences co-led Kailera's $400 million Series A and backed the company through its record-breaking IPO.

Timeline

December 2017 April 2026

13 events Latest: April 18th, 2026 · 1 month ago Showing 8 of 13

Tap a bar to jump to that date

April 2026
Kailera surges 62.5% in record-breaking $625M biotech IPO
Latest Market

Kailera Therapeutics began trading on Nasdaq under ticker KLRA, with shares closing at $26 — a 62.5% gain over the $16 IPO price. The $625 million raise surpassed Moderna's 2018 record as the largest biotech IPO in history.
April 18th, 2026
FDA approves Eli Lilly's oral obesity pill orforglipron
Regulatory

Eli Lilly's orforglipron became the second oral GLP-1 approved for obesity, setting up a direct pill-versus-pill competition with Novo Nordisk's oral Wegovy.
April 1st, 2026
February 2026
Oral ribupatide shows 12.1% weight loss in Phase 2
Clinical

Kailera and Hengrui reported that once-daily oral ribupatide produced 12.1% mean weight loss at 26 weeks in a 166-patient trial, with 59.1% of participants on the 25 mg dose losing at least 10% of body weight.
February 10th, 2026
January 2026
Kailera begins Phase 3 trials for injectable ribupatide
Clinical

Kailera announced the first patients randomized in its KaiNETIC global Phase 3 program — three trials enrolling a combined 4,700 adults to evaluate weekly ribupatide injections over 76 weeks.
January 12th, 2026
Oral Wegovy launches in the United States
Market

Novo Nordisk began selling its Wegovy pill at U.S. pharmacies, priced between $149 and $299 per month. The drug hit 50,000 weekly prescriptions within three weeks.
January 5th, 2026
December 2025
FDA approves oral Wegovy, first GLP-1 pill for obesity
Regulatory

Novo Nordisk's oral semaglutide (Wegovy pill) won FDA approval for weight management, showing 16.6% mean weight loss in the OASIS 4 trial — comparable to the injectable version.
December 22nd, 2025
October 2024
Kailera launches with $400 million Series A
Business

Kailera Therapeutics emerged from stealth with $400 million in Series A funding co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments to develop next-generation obesity therapies.
October 1st, 2024
May 2024
Kailera licenses obesity drug portfolio from Hengrui
Business

Kailera Therapeutics acquired exclusive global rights (outside greater China) to four metabolic disease assets from Jiangsu Hengrui Pharmaceuticals, including the dual GLP-1/GIP agonist ribupatide.
May 1st, 2024
November 2023
Zepbound approved, intensifying the obesity drug race
Regulatory

The FDA approved tirzepatide as Zepbound for chronic weight management. With up to 22.5% weight loss in trials, Eli Lilly now had a direct competitor to Wegovy with superior efficacy data.
November 8th, 2023
August 2023
Semaglutide shows cardiovascular benefit beyond weight loss
Clinical

Novo Nordisk's SELECT trial demonstrated that semaglutide reduced major cardiovascular events in obese patients — expanding the medical rationale for GLP-1 drugs beyond weight management alone.
August 8th, 2023
May 2022
Eli Lilly enters the field with Mounjaro
Regulatory

The FDA approved tirzepatide (Mounjaro), a dual GLP-1/GIP agonist, for type 2 diabetes. Its superior weight-loss results foreshadowed a direct challenge to Novo Nordisk's dominance.
May 13th, 2022
June 2021
Wegovy becomes first GLP-1 approved for weight loss
Regulatory

The FDA approved higher-dose semaglutide (Wegovy) for chronic weight management in adults with obesity, creating an entirely new treatment category. Clinical trials showed roughly 15-17% body weight reduction.
June 4th, 2021
December 2017
FDA approves Ozempic, launching the GLP-1 era
Regulatory

The Food and Drug Administration approved Novo Nordisk's semaglutide injection (Ozempic) for type 2 diabetes, establishing the drug class that would later reshape obesity treatment.
December 5th, 2017

#timeline [x-show="expanded"] { display: revert !important; opacity: 1 !important; } #timeline .timeline-toggle-btn { display: none; }

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

December 2018

Moderna's Record Biotech IPO (2018)

Moderna, then an unproven messenger RNA (mRNA) therapeutics company with no approved products, raised $604 million in the largest biotech IPO at the time, pricing at $23 per share. Many analysts questioned the valuation of a company built entirely on an experimental technology platform.

Then

Shares dropped below the IPO price within weeks, and skeptics called the offering overhyped. The company continued to burn cash developing its mRNA pipeline.

Now

The COVID-19 pandemic vindicated the bet spectacularly. Moderna's mRNA vaccine generated tens of billions in revenue, and the stock reached over $400 per share at its peak — a roughly 17-fold return from the IPO price.

Why this matters now

Kailera's $625 million raise directly surpasses Moderna's record. Both companies went public on the promise of a transformative therapeutic platform with no approved products. The parallel raises the central question: is Kailera another visionary bet, or does the crowded obesity field make the comparison less apt?

May 2022 – November 2023

Eli Lilly's Tirzepatide Disruption (2022-2023)

Eli Lilly's tirzepatide, a dual GLP-1/GIP agonist, won FDA approval for diabetes (as Mounjaro) in May 2022 and for obesity (as Zepbound) in November 2023. Its SURMOUNT trials showed up to 22.5% weight loss — significantly outperforming Novo Nordisk's semaglutide and proving that dual-receptor targeting could deliver superior results.

Then

Lilly rapidly gained market share, and Novo Nordisk's stock fell as investors reassessed its competitive position. Zepbound demand outstripped supply within weeks of launch.

Now

Lilly overtook Novo Nordisk in GLP-1 market share by 2026, with projected revenues of $80-83 billion. The success validated dual-agonist approaches and triggered a wave of investment in multi-target obesity drugs.

Why this matters now

Kailera's ribupatide is also a dual GLP-1/GIP agonist, the same mechanism that allowed Lilly to leapfrog Novo Nordisk. The precedent shows that second-movers with superior or differentiated mechanisms can capture enormous value — but also that the bar for efficacy keeps rising.

2020 – present

China-to-Global Drug Licensing Boom (2020s)

A wave of Western biotech companies began licensing drug candidates from Chinese pharmaceutical firms, reversing the traditional flow of innovation. Companies like Legend Biotech (partnered with Johnson & Johnson on the CAR-T therapy Carvykti) demonstrated that Chinese-developed therapies could win global regulatory approval and commercial success.

Then

Deal volume surged, with billions in licensing fees flowing to Chinese drugmakers. U.S.-listed biotechs built around Chinese-origin assets attracted significant venture capital.

Now

The trend established China as a legitimate source of globally competitive drug candidates, though it also raised questions about intellectual property protection, regulatory scrutiny, and geopolitical risk.

Why this matters now

Kailera's entire pipeline — all four candidates — is licensed from Hengrui Pharmaceuticals. The company's success or failure will be a bellwether for the viability of the China-to-global licensing model in the competitive obesity drug space.